Prepulse inhibition and latent inhibition: The role of dopamine in the medial prefrontal cortex

Neuroscience

Volumn 75, Issue 2, 1996, Pages 535-542

  Ellenbroek, B A ^a   Budde, S ^a   Cools, A R ^a  

^a Dept of Psychoneuropharmacology ^*  (Netherlands)

Author keywords

animal model; D1 receptors; D2 receptors; latent inhibition; prefrontal cortex; prepulse inhibition

Indexed keywords

DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; DOPAMINE RECEPTOR BLOCKING AGENT; SULPIRIDE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; MALE; NONHUMAN; PREFRONTAL CORTEX; PREPULSE INHIBITION; PRIORITY JOURNAL; RAT; SCHIZOPHRENIA;

EID: 0030601692     PISSN: 03064522     EISSN: None     Source Type: Journal    
DOI: 10.1016/0306-4522(96)00307-7     Document Type: Article

References (39)

1. Andreasen N. C., Ehrhardt J. C., Swayze V. W. II, Alliger A. J., Yuh W. T. C., Cohen G., Ziebell S. Magnetic resonance imaging of the brain in schizophrenia: the pathophysiologic significance of structural abnormalities. Archs gen. Psychiat. 47:1990;35-44.
2. Bakshi V. P., Geyer M. A. Antagonism of phencyclidine-induced deficits in prepulse inhibition by the putative atypical antipsychotic olanzapine. Psychopharmacology. 122:1995;198-201.
3. Baruch I., Hemsley D. R., Gray J. A. Differential performance of acute and chronic schizophrenics in a latent inhibition task. J. nerv. ment. Dis. 176:1988;598-606.
4. Bogerts B., Falkai P., Greve B., Schneider T., Pfeiffer U. The neuropathology of schizophrenia: past and present. J. Hirnforsch. 34:1993;193-205.
5. Braff D. L., Grillon C., Geyer M. A. Gating and habituation of the startle reflex in schizophrenic patients. Archs gen. Psychiat. 49:1992;206-215.
6. Broersen L. M., Heinsbroek R. P. W., De Bruin J. P. C., Olivier B. Effects of local application of dopaminergic drugs into the medial prefrontal cortex. Biol. Psychiat. 00:1996;000-000.
7. Brown R., Colter M., Corsellis J. A. N., Crow T. J., Frith C. D., Johnstone E. C., Owens D. G. C., Robert G. W. Postmortem evidence of structural brain changes in schizophrenia. Archs gen. Psychiat. 43:1986;36-42.
8. Bruton C. J., Crow T. J., Frith C. D., Johnstone E. C., Owens D. G., Roberts G. W. Schizophrenia and the brain: a prospective clinico-neuropathological study. Psychol. Med. 20:1990;285-304.
9. Bubser M., Koch M. Prepulse inhibition of the acoustic startle response of rats is reduced by 6-hydroxydopamine lesions of the medial prefrontal cortex. Psychopharmacology. 113:1994;487-492.
10. Carboni E., Tanda G. L., Frau R., DiChiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 55:1990;1067-1070.
11. Chen J., Paredes W., Van Praag H. M., Lowinson J. H., Gardner E. L. Presynaptic dopamine release is enhanced by 5-HT3 receptor activation in medial prefrontal cortex of freely moving rats. Synapse. 10:1992;264-266.
12. Christensen A. V. Classification of neuroleptics: implications for tardive dyskinesia. Pol. J. Pharmac. Pharm. 37:1985;295-309.
13. Deutch A. Y., Clark W. A., Roth R. H. Prefrontal cortical dopamine depletion enhances the responsiveness of mesolimbic dopamine neurons to stress. Brain Res. 521:1990;311-315.
14. Ellenbroek B. A., Cools A. R. Animal models with construct validity for schizophrenia. Behav. Pharmac. 1:1990;469-490.
15. Ellenbroek B. A., Cools A. R. Maternal separation reduces latent inhibition in the conditioned taste aversion paradigm. Neurosci. Res. Commun. 17:1995;27-33.
16. Ellenbroek B. A., Geyer M. A., Cools A. R. The behavior of APO-SUS rats in animal models with construct validity for schizophrenia. J. Neurosci. 15:1995;7604-7611.
17. Ellenbroek B. A., Knobbout D. A., Cools A. R. The role of mesolimbic and nigrostriatal dopamine in latent inhibition as measured with the conditioned taste aversion paradigm. Psychopharmacology. 00:1996;000-000.
18. Geyer M. A. and Markou A. (1995) Animal models of psychiatric disorders. In Psychopharmacology: Fourth Generation of Progress (eds Bloom F.E. and Kupfer D.J.), pp. 787-798. Raven Press, New York.
19. Gray N. S., Pilowsky L. S., Gray J. A., Kerwin R. W. Latent inhibition in drug naive schizophrenics: relationship to duration of illness and dopamine D2 binding using SPECT. Schizophr. Res. 17:1995;95-107.
20. Gresch P. J., Sved A. F., Zigmond M. J., Finlay J. M. Local influence of endogenous norepinephrine on extracellular dopamine in rat medial prefrontal cortex. J. Neurochem. 65:1995;111-116.
21. 2 dopamine receptor antagonists reverse prepulse inhibition deficits in an animal model for schizophrenia. Psychopharmacology. 115m:1994;447-453.
22. Koch M., Bubser M. Deficient sensorimotor gating after 6-hydroxydopamine lesion of the rat medial prefrontal cortex is reversed by haloperidol. Eur. J. Neurosci. 6:1994;1837-1845.
23. Louilot A., Leoal M., Simon H. Opposite influences of dopaminergic pathways to the prefrontal cortex or the septum on the dopaminergic transmission in the nucleus accumbens. An in vivo voltammetric study. Neuroscience. 29:1989;45-56.
24. Lubow R. (1989) Latent Inhibition and Conditioned Attention Theory. Cambridge University Press, New York.
25. 3H]SCH39166, a new D1-selective radioligand: in vitro and in vivo binding analyses. J. Neurochem. 57:1991;2001-2010.
26. Mitchell J. B., Gratton A. Partial dopamine depletion of the prefrontal cortex leads to enhanced mesolimbic dopamine release elicited by repeated exposure to naturally reinforcing stimuli. J. Neurosci. 12:1992;3609-3618.
27. Pakkenberg B. Post mortem study of chronic schizophrenic brains. Br. J. Psychiat. 151:1987;744-752.
28. Paxinos G. and Watson C. (1986) The Rat Brain in Stereotaxic Coordinates, 2nd edn. Academic Press, San Diego.
29. Plum F. Prospects for research on schizophrenia. 3. Neurophysiology, neuropathological findings. Neurosci. Res. Prog. Bull. 10:1972;384-388.
30. Roberts G. W., Crow T. J. The neuropathology of schizophrenia - a progress report. Br. med. Bull. 43:1987;599-615.
31. Schmidt C. J., Fadayel G. M. The selective 5-HT2A receptor antagonist, MDL 100,907, increases dopamine efflux in the prefrontal cortex of the rat. Eur. J. Pharmac. 273:1995;273-279.
32. Schwarzkopf S. B., Bruno J. P., Mitra T. Effects of haloperiol and SCH 23390 on acoustic startle and prepulse inhibition under basal and stimulated conditions. Prog. Neuropsychopharmac. biol. Psychiat. 17:1993;1023-1036.
33. Swerdlow N. R., Braff D. L., Geyer M. A., Koob G. F. Central dopamine hyperactivity in rats mimics abnormal acoustic startle response in schizophrenics. Biol. Psychiat. 21:1986;23-33.
34. Swerdlow N. R., Caine S. B., Geyer M. A. Regionally selective effects of intracerebral dopamine infusion on sensorimotor gating of the startle reflex in rats. Psychopharmacology. 108:1992;189-195.
35. Tassin J. P. NE/DA interactions in prefrontal cortex and their possible roles as neuromodulators in schizophrenia. J. neural Transm. 36(Suppl.):1992;135-162.
36. Vezina P., Blanc G., Glowinski J., Tassin J. P. Opposed behavioural outputs of increased dopamine transmission in prefrontocortical and subcortical areas: a role for the cortical D-1 dopamine receptor. Eur. J. Neurosci. 3:1991;1001-1007.
37. Wan F. J., Swerdlow N. R. Intra-accumbens infusion of quinpirole impairs sensorimotor gating of acoustic startle in rats. Psychopharmacology. 113:1993;103-109.
38. Weinberger D. R., Lipska B. K. Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground. Schizophr. Res. 16:1995;87-110.
39. Zec R. F., Weinberger D. R. The relationship between CT scan findings and neuropsychological performance in chronic schizophrenia. Psychiat. Clin. N. Am. 9:1986;49-61.